Revision history of "Any Cycle The second Trial of Osimertinib as the FirstLine Management of NonSmall Mobile or portable Carcinoma of the lung Holding Activating EGFR Variations within Moving Tumor Genetic LiquidLungOCohort One"

From EECH Central
Jump to: navigation, search

Diff selection: Mark the radio boxes of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

  • (cur | prev) 09:32, 24 April 2024‎ Baboonthrone6 (Talk | contribs)‎ . . (3,492 bytes) (+3,492)‎ . . (Created page with "Fifteen; 95%CI 3.78-1.70; p = 0.Forty eight). Human immunodeficiency virus has not been related to MACE (aOR 0.Ninety nine; 95%CI 0.69-1.46, p = 0.Ninety one), COVID s...")
Retrieved from "http://eechcentral.simhq.com/index.php?title=Any_Cycle_The_second_Trial_of_Osimertinib_as_the_FirstLine_Management_of_NonSmall_Mobile_or_portable_Carcinoma_of_the_lung_Holding_Activating_EGFR_Variations_within_Moving_Tumor_Genetic_LiquidLungOCohort_One"